# US 2020/0390752 A1 · Therapeutic agent for liver diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390752 A1
- Document ID: US20200390752A1
- Status: Published application
- Kind: A1
- Application number: 16/481,307
- Filed: 2018-09-14
- Published: 2020-12-17
- Earliest claimed: 2018-01-11
- Assignees: Aptabio Therapeutics Inc.
- Applicants: Aptabio Therapeutics Inc.
- Inventors: Sung Hwan Moon; Soo Jin Lee; Sung Chan Lee; Yun Soo Bae
- Web page: https://patentgrep.com/patent/US20200390752A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.

## Claims

### Claim 1

A pharmaceutical composition for preventing, alleviating or treating a liver disease comprising, as an active ingredient, at least one compound selected from a pyrazole-based compound represented by the following Formula 1 and a pharmaceutically acceptable salt thereof:
wherein R is a C1-C10 linear or branched alkyl group.

### Claim 2 (depends on 1)

The pharmaceutical composition for preventing, alleviating or treating a liver disease according to claim 1, wherein the pharmaceutical composition comprises, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition for preventing, alleviating or treating a liver disease according to claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of an alkali metal salt, an alkaline earth metal salt, a salt with an inorganic acid, a salt with an organic acid, and a salt with an acidic amino acid.

### Claim 4 (depends on 1)

The pharmaceutical composition for preventing, alleviating or treating a liver disease according to claim 1, wherein the pharmaceutically acceptable salt is hydrochloride.

### Claim 5 (depends on 1)

The pharmaceutical composition for preventing, alleviating or treating a liver disease according to claim 1, wherein the liver disease is non-alcoholic fatty liver disease (NAFLD).

### Claim 6 (depends on 5)

The pharmaceutical composition for preventing, alleviating or treating a liver disease according to claim 5, wherein the non-alcoholic fatty liver disease (NAFLD) comprises at least one of simple steatosis, non-alcoholic steatohepatitis (NASH) and cirrhosis.

### Claim 7 (depends on 1)

The pharmaceutical composition for preventing, alleviating or treating a liver disease according to claim 1, wherein the pharmaceutical composition is prepared in the form of a formulation selected from the group consisting of injections, granules, tablets, pills, capsules, gels, syrups, suspensions, emulsions, droplets and liquids.

### Claim 8

A therapeutic or prophylactic agent for simple steatosis comprising, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.

### Claim 9

A therapeutic or prophylactic agent for non-alcoholic steatohepatitis comprising, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.

### Claim 10

A therapeutic or prophylactic agent for cirrhosis comprising, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.
